GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Edwards Lifesciences Corp (LTS:0REN) » Definitions » Piotroski F-Score

Edwards Lifesciences (LTS:0REN) Piotroski F-Score : 6 (As of May. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Edwards Lifesciences Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Edwards Lifesciences's Piotroski F-Score or its related term are showing as below:

LTS:0REN' s Piotroski F-Score Range Over the Past 10 Years
Min: 5   Med: 6   Max: 8
Current: 6

During the past 13 years, the highest Piotroski F-Score of Edwards Lifesciences was 8. The lowest was 5. And the median was 6.


Edwards Lifesciences Piotroski F-Score Historical Data

The historical data trend for Edwards Lifesciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Edwards Lifesciences Piotroski F-Score Chart

Edwards Lifesciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 6.00 8.00 5.00 6.00

Edwards Lifesciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 5.00 5.00 6.00 6.00

Competitive Comparison of Edwards Lifesciences's Piotroski F-Score

For the Medical Devices subindustry, Edwards Lifesciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edwards Lifesciences's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Edwards Lifesciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Edwards Lifesciences's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 276.513 + 346.256 + 319.89 + 312.698 = CHF1,255 Mil.
Cash Flow from Operations was 30.253 + 370.185 + 118.132 + -47.54 = CHF471 Mil.
Revenue was 1377.792 + 1332.218 + 1326.69 + 1420.161 = CHF5,457 Mil.
Gross Profit was 1068.955 + 1016.998 + 1018.043 + 1077.516 = CHF4,182 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(8006.686 + 8107.202 + 8429.972 + 8097.295 + 8651.676) / 5 = CHF8258.5662 Mil.
Total Assets at the begining of this year (Mar23) was CHF8,007 Mil.
Long-Term Debt & Capital Lease Obligation was CHF599 Mil.
Total Current Assets was CHF3,706 Mil.
Total Current Liabilities was CHF987 Mil.
Net Income was 394.289 + 334.329 + 371.149 + 315.133 = CHF1,415 Mil.

Revenue was 1332.958 + 1283.783 + 1256.076 + 1350.86 = CHF5,224 Mil.
Gross Profit was 1071.586 + 1036.759 + 1015.817 + 1045.908 = CHF4,170 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(7825.455 + 8174.032 + 8407.56 + 7725.293 + 8006.686) / 5 = CHF8027.8052 Mil.
Total Assets at the begining of last year (Mar22) was CHF7,825 Mil.
Long-Term Debt & Capital Lease Obligation was CHF613 Mil.
Total Current Assets was CHF3,015 Mil.
Total Current Liabilities was CHF1,001 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Net Income (TTM) was 1,255. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Edwards Lifesciences's current Cash Flow from Operations (TTM) was 471. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=1255.357/8006.686
=0.15678859

ROA (Last Year)=Net Income/Total Assets (Mar22)
=1414.9/7825.455
=0.18080738

Edwards Lifesciences's return on assets of this year was 0.15678859. Edwards Lifesciences's return on assets of last year was 0.18080738. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Edwards Lifesciences's current Net Income (TTM) was 1,255. Edwards Lifesciences's current Cash Flow from Operations (TTM) was 471. ==> 471 <= 1,255 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=599.272/8258.5662
=0.07256369

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=613.329/8027.8052
=0.07640058

Edwards Lifesciences's gearing of this year was 0.07256369. Edwards Lifesciences's gearing of last year was 0.07640058. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=3705.906/987.057
=3.7545005

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=3014.539/1001.391
=3.0103516

Edwards Lifesciences's current ratio of this year was 3.7545005. Edwards Lifesciences's current ratio of last year was 3.0103516. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Edwards Lifesciences's number of shares in issue this year was 604.1. Edwards Lifesciences's number of shares in issue last year was 610.9. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4181.512/5456.861
=0.76628523

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=4170.07/5223.677
=0.79830166

Edwards Lifesciences's gross margin of this year was 0.76628523. Edwards Lifesciences's gross margin of last year was 0.79830166. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=5456.861/8006.686
=0.68153803

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=5223.677/7825.455
=0.66752374

Edwards Lifesciences's asset turnover of this year was 0.68153803. Edwards Lifesciences's asset turnover of last year was 0.66752374. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+1+1+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Edwards Lifesciences has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Edwards Lifesciences  (LTS:0REN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Edwards Lifesciences Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Edwards Lifesciences's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Edwards Lifesciences (LTS:0REN) Business Description

Address
One Edwards Way, Irvine, CA, USA, 92614
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.

Edwards Lifesciences (LTS:0REN) Headlines

No Headlines